Construction of a Novel Mitochondria-Associated Gene Model for Assessing ESCC Immune Microenvironment and Predicting Survival
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Esophageal squamous cell carcinoma (ESCC) is among the most common malignant tumors of the digestive tract, with the sixth highest fatality rate worldwide. The ESCC-related dataset, GSE20347, was downloaded from the Gene Expression Omnibus (GEO) database, and weighted gene coexpression network analysis was performed to identify genes that are highly correlated with ESCC. A total of 91 transcriptome expression profiles and their corresponding clinical information were obtained from The Cancer Genome Atlas database. A mitochondria-associated risk (MAR) model was constructed using the least absolute shrinkage and selection operator Cox regression analysis and validated using GSE161533. The tumor microenvironment and drug sensitivity were explored using the MAR model. Finally, in vitro experiments were performed to analyze the effects of hub genes on the proliferation and invasion abilities of ESCC cells. To confirm the predictive ability of the MAR model, we constructed a prognostic model and assessed its predictive accuracy. The MAR model revealed substantial differences in immune infiltration and tumor microenvironment characteristics between high- and low-risk populations and a substantial correlation between the risk scores and some common immunological checkpoints. AZD1332 and AZD7762 were more effective for patients in the low-risk group, whereas Entinostat, Nilotinib, Ruxolutinib, and Wnt.c59 were more effective for patients in the high-risk group. Knockdown of TYMS significantly inhibited the proliferation and invasive ability of ESCC cells in vitro. Overall, our MAR model provides stable and reliable results and may be used as a prognostic biomarker for personalized treatment of patients with ESCC
Abstract
Esophageal squamous cell carcinoma (ESCC) is among the most common malignant tumors of the digestive tract, with the sixth highest fatality rate worldwide. The ESCC-related dataset, GSE20347, was downloaded from the Gene Expression Omnibus (GEO) database, and weighted gene coexpression network analysis was performed to identify genes that are highly correlated with ESCC. A total of 91 transcriptome expression profiles and their corresponding clinical information were obtained from The Cancer Genome Atlas database. A mitochondria-associated risk (MAR) model was constructed using the least absolute shrinkage and selection operator Cox regression analysis and validated using GSE161533. The tumor microenvironment and drug sensitivity were explored using the MAR model. Finally, in vitro experiments were performed to analyze the effects of hub genes on the proliferation and invasion abilities of ESCC cells. To confirm the predictive ability of the MAR model, we constructed a prognostic model and assessed its predictive accuracy. The MAR model revealed substantial differences in immune infiltration and tumor microenvironment characteristics between high- and low-risk populations and a substantial correlation between the risk scores and some common immunological checkpoints. AZD1332 and AZD7762 were more effective for patients in the low-risk group, whereas Entinostat, Nilotinib, Ruxolutinib, and Wnt.c59 were more effective for patients in the high-risk group. Knockdown of TYMS significantly inhibited the proliferation and invasive ability of ESCC cells in vitro. Overall, our MAR model provides stable and reliable results and may be used as a prognostic biomarker for personalized treatment of patients with ESCC
참고문헌 (48)
- Arnold M, "Global burden of 5 major types of gastrointestinal cancer", Gastroenterology, 159, pp.335~349 (2020)
- Morgan E, "obal Landscape of eophageal suamous cll crcinoma and eophageal aenocarcinoma icidence and mrtality in 2020 and pojections to 2040: new etimates from GLOBOCAN 2020", Gastroenterology, 163, pp.649~658 (2022)
- Tanprasert P, "Targeting mitochondria as a therapeutic anti-gastric cancer approach", Apoptosis, 27, pp.163~183 (2022)
- Zheng ZY, "STAT3beta disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma", Cancer Lett, 522, pp.171~183 (2021)
- He JZ, "Spatial analysis of stromal signatures has identified invasive front carcinoma-associated fibroblasts as suppressors of the antitumor immune response in esophageal cancer", J. Exp. Clin. Cancer Res, 42, pp.136~ (2023)
- Cheng J, "Construction and evaluation of a risk score model for lymph node metastasis-associated circadian clock genes in esophageal squamous carcinoma", Cells, 11, pp.3432~ (2022)
- Jia W, "Purinergic signalling in cancer therapeutic resistance : from mechanisms to targeting strategies", Drug Resist. Updat, 70, pp.100988~ (2023)
- Sheban F, "It takes two to tango : the role of tumor-associated macrophages in T cell-directed immune checkpoint blockade therapy", Front. Immunol, 14, pp.1183578~ (2023)
- Carlisle JW, "An update on the immune landscape of lung, head, and neck cancers", CA Cancer J. Clin, 70, pp.505~517 (2020)
- Hu N, "Genome wide analysis of DNA copy number neutral loss of heterozygosity(CNNLOH)and its relationship to gene expression in esophageal squamous cell carcinoma", BMC Genomics, 11, pp.576~ (2010)
- Tabah A, "epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study", Intensive Care Med, 49, pp.178~190 (2023)
- Colaprico A, "CGAbiolinks : an R", Bioconductor package for integrative analysis of TCGA data, 2016, pp.44, e71~
- Chang J, "Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinoma", J. Transl. Med, 21, pp.191~ (2023)
- Langfelder P, "WGCNA : an R package for weighted correlation network analysis", BMC Bioinformatics, 9, pp.559~ (2008)
- Ritchie ME, "limma powers differential expression analyses for RNA sequencing and microarray studies", Nucleic Acids Res, 43, pp.e47~ (2015)
- Gustavsson EK, "ggtranscript: an R. package for the visualization and interpretation of transcript isoforms using ggplot2", Bioinformatics, 38, pp.3844~3846 (2022)
- Chu F, "Compact broad learning system based on fused lasso and smooth lasso", IEEE Trans. Cybern, 54, pp.435~448 (2024)
- Robin X, "pROC : an open-source package for R and S+ to analyze and compare ROC curves", BMC Bioinformatics, 12, pp.77~ (2011)
- Shu Q, "Identification and experimental validation of mitochondria-related genes biomarkers associated with immune infiltration for sepsis", Front. Immunol, 14, pp.1184126~ (2023)
- Yoshihara K, "Inferring tumour purity and stromal and immune cell admixtures from expression data", Nat. Commun, 4, pp.2612~ (2013)
- Ye Y, "A novel defined a pyroptosis-related gene signature for predicting the prognosis of ovarian cancer", Cell Death Discov, 7, pp.71~ (2021)
- Newman AM, "Determining of cell type abundance and expression in bulk tissues using digital cytometry", Nat. Biotechnol, 37, pp.773~782 (2019)
- Yang W, "Genomics of Drug Sensitivity in Cancer(GDSC) : a resource for therapeutic biomarker discovery in cancer cells", Nucleic Acids Res, 41, pp.955~961 (2013)
- Geeleher P, "pRRophetic : an rpackage for the prediction of clinical chemotherapeutic response from tumor gene expression levels", PLoS One, 9, pp.e107468~ (2014)
- Rao X, "An improvement of the 2ˆ(-delta delta CT)method for quantitative real-time polymerase chain reaction data analysis", Biostat. Bioinforma. Biomath, 3, pp.71~85 (2013)
- Ajani JA, "Esophageal and esophagogastric junction cancers, version 1.2015", J. Natl. Compr. Canc. Netw, 13, pp.194~227 (2015)
- Pape M, "Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer : a population-based study", Cancer Sci, 113, pp.1038~1046 (2022)
- Wilkinson MS, "Blood-based bioenergetics : a liquid biopsy of mitochondrial dysfunction in disease", Trends Endocrinol. Metab, 34, pp.554~570 (2023)
- Vercellino I, "Small cell lung cancer : novel treatments beyond immunotherapy", Nat. Rev. Mol. Cell. Biol, 23, pp.141~161 (2022)
- Wu Q, "Characterization of early myocardial inflammation in ischemia-reperfusion injury", Front. Immunol, 13, pp.1081719~ (2023)
- Zampieri LX, "Mitochondrial transfer in cancer : a comprehensive review", Int. J. Mol. Sci, 22, pp.3245~ (2021)
- Canyelles-Nino M, "Hydroperoxidation of docosahexaenoic acid by human ALOX12 and pigALOX15-mini-LOX", Int. J. Mol. Sci, 24, pp.6064~ (2023)
- Nie J, "A novel ferroptosis related gene signature for prognosis prediction in patients with colon cancer", Front. Oncol, 11, pp.654076~ (2021)
- Weng S, "ALOX12 : a novel insight into bevacizumab response, immunotherapy effect, and prognosis of colorectal cancer", Front. Immunol, 13, pp.910582~ (2022)
- Chen J, "Inhibition of arachidonate lipoxygenase12 targets lung cancer by inhibiting EMT and suppressing RhoA and NF-kappaB activity", Biochem. Biophys. Res. Commun, 524, pp.803~809 (2020)
- Song J, "A novel ferroptosis-related biomarker signature to predict overall survival of esophageal squamous cell carcinoma", Front. Mol. Biosci, 8, pp.675193~ (2021)
- Guijarro MV, "TYMS promotes genomic instability and tumor progression in Ink4a", Arf null background, 2023, pp.42, 1926~1939
- Fu Z, "TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer", Medicine (Baltimore), 98, pp.e18487~ (2019)
- Song S, "Diagnostic and prognostic value of thymidylate synthase expression in breast cancer", Clin. Exp. Pharmacol. Physiol, 48, pp.279~287 (2021)
- Wang L, "Correction : FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma", Cancer Cell Int, 22, pp.384~ (2022)
- Chen W, "In situ engineering of tumor-associated macrophages via a nanodrugdelivering-drug(beta-Elemene@Stanene)strategy for enhanced cancer chemo-immunotherapy", Angew. Chem. Int. Ed. Engl, 62, pp.e202308413~ (2023)
- Serafini P, "Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells", Cancer Res, 68, pp.5439~5449 (2008)
- Izzi V, "an-Cancer analysis of the genomic alterations and mutations of the matrisome", Cancers(Basel), 12, pp.2046~ (2020)
- Guan Q, "Strategies to reinvigorate exhausted CD8(+)T cells in tumor microenvironment", Front. Immunol, 14, pp.1204363~ (2023)
- Ko KP, "Key Genetic determinants of Cell Carcinoma initiation and immune evasion", Gastroenterology, 165, pp.613~628 (2023)
- Bolf EL, "Dasatinib and trametinib promote antitumor metabolic activity", Cells, 12, pp.1374~ (2023)
- Xu B, "Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer : a multicenter, randomized, double-blind, placebocontrolled, phase 3 trial", Acta Pharm Sin B, 13, pp.2250~2258 (2023)
- Sausville E, "Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors", Cancer Chemother. Pharmacol, 73, pp.539~549 (2014)